Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP421705.RAqZ1nvGhlCI2ihnCNytreX7_RMSHFBkwZsKTRrtYYvDo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP421705.RAqZ1nvGhlCI2ihnCNytreX7_RMSHFBkwZsKTRrtYYvDo130_assertion type Assertion NP421705.RAqZ1nvGhlCI2ihnCNytreX7_RMSHFBkwZsKTRrtYYvDo130_head.
- NP421705.RAqZ1nvGhlCI2ihnCNytreX7_RMSHFBkwZsKTRrtYYvDo130_assertion description "[Patients with stage IV neuroblastoma over the age of 500 days without MYCN amplification have a survival rate of <30% and there are currently no reliable means of predicting which of these patients will survive or succumb to the disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP421705.RAqZ1nvGhlCI2ihnCNytreX7_RMSHFBkwZsKTRrtYYvDo130_provenance.
- NP421705.RAqZ1nvGhlCI2ihnCNytreX7_RMSHFBkwZsKTRrtYYvDo130_assertion evidence source_evidence_literature NP421705.RAqZ1nvGhlCI2ihnCNytreX7_RMSHFBkwZsKTRrtYYvDo130_provenance.
- NP421705.RAqZ1nvGhlCI2ihnCNytreX7_RMSHFBkwZsKTRrtYYvDo130_assertion SIO_000772 18765546 NP421705.RAqZ1nvGhlCI2ihnCNytreX7_RMSHFBkwZsKTRrtYYvDo130_provenance.
- NP421705.RAqZ1nvGhlCI2ihnCNytreX7_RMSHFBkwZsKTRrtYYvDo130_assertion wasDerivedFrom befree-20140225 NP421705.RAqZ1nvGhlCI2ihnCNytreX7_RMSHFBkwZsKTRrtYYvDo130_provenance.
- NP421705.RAqZ1nvGhlCI2ihnCNytreX7_RMSHFBkwZsKTRrtYYvDo130_assertion wasGeneratedBy ECO_0000203 NP421705.RAqZ1nvGhlCI2ihnCNytreX7_RMSHFBkwZsKTRrtYYvDo130_provenance.